Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06669403 · ClinicalTrials.gov registry record · Phase 1
OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis
A Phase 1 study, sponsored by Op-T.
- Not yet
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT06669403 is a Phase 1 study that has not yet begun recruiting, run by Op-T. The registered enrollment target is 26 participants.
The verdict
NCT06669403, a Phase 1 study, has not yet begun recruiting, sponsored by Op-T.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
OPT101-100-40 is a multicenter, randomized, placebo-controlled, multiple-ascending-dose, sequential-group, investigator- and participant-blinded, sponsor-unblinded, study of OPT101 vs placebo when administered for up to 4 days to patients admitted to the hospital for treatment of Community Acquired Pneumonia (CAP) with sepsis. This study will be performed in patients with Community Acquired Pneumonia (CAP) with Sepsis, who are 18 years or older to evaluate the safety and tolerability of OPT101 in a population with elevated levels of pathologic CD40.
Interventions
- OTHER Placebo
- DRUG OPT101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2025-12 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06669403
The ClinicalTrials.gov registry entry for NCT06669403 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Op-T, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06669403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06669403 about?
NCT06669403 is a clinical study titled "OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis". OPT101-100-40 is a multicenter, randomized, placebo-controlled, multiple-ascending-dose, sequential-group, investigator- and participant-blinded, sponsor-unblinded, study of OPT101 vs placebo when administered for up to 4 days to patients admitted to the hospital for treatment of Community Acquired ...
What is the current status of trial NCT06669403?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2025-12. Estimated completion is 2026-05.
What interventions are being tested in trial NCT06669403?
The interventions under investigation include: Placebo (OTHER), OPT101 (DRUG).
Who is sponsoring clinical trial NCT06669403?
This trial is sponsored by Op-T, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.